Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- TPST
- Price
- 3.07
- Stock movement up
- +0.46 (17.62%)
- Company name
- Tempest Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 15.13M
- Ent value
- 18.40M
- Price/Sales
- 15.56
- Price/Book
- 2.38
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -67.94%
- 1 year return (CAGR)
- 246.27%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
TPST does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 15.56 |
| Price to Book | 2.38 |
| EV to Sales | 18.93 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 4.93M |
| EPS (TTM) | -8.12 |
| FCF per share (TTM) | -7.52 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 972.00K |
| Gross profit (TTM) | 42.00K |
| Operating income (TTM) | -36.42M |
| Net income (TTM) | -36.05M |
| EPS (TTM) | -8.12 |
| EPS (1y forward) | -16.02 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 4.32% |
| Operating margin (TTM) | -3746.60% |
| Profit margin (TTM) | -3709.26% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 7.51M |
| Net receivables | 0.00 |
| Total current assets | 8.10M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 10.03M |
| Total assets | 17.13M |
| Accounts payable | 922.00K |
| Short/Current long term debt | 8.40M |
| Total current liabilities | 3.52M |
| Total liabilities | 10.78M |
| Shareholder's equity | 6.35M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -33.40M |
| Capital expenditures (TTM) | 6.00K |
| Free cash flow (TTM) | -33.40M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -568.14% |
| Return on Assets | -210.49% |
| Return on Invested Capital | -481.17% |
| Cash Return on Invested Capital | -445.76% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.76 |
| Daily high | 3.15 |
| Daily low | 2.73 |
| Daily Volume | 391K |
| All-time high | 12028.50 |
| 1y analyst estimate | 9.00 |
| Beta | -2.26 |
| EPS (TTM) | -8.12 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| TPST | S&P500 | |
| Current price drop from All-time high | -99.97% | -0.89% |
| Highest price drop | -100.00% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -99.96% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
15.13M
Marketcap category
Small-cap
Description
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Employees
24
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page